

# TAP-GRIN: Interventional Study on Patients With GRIN-related Neurodevelopmental Disorders

NCT07377032

---

<b>Status</b>	RECRUITING
<b>Phase</b>	Phase 3
<b>Sponsor</b>	Meyer Children's Hospital IRCCS
<b>Enrollment</b>	40 participants

## Key Eligibility Criteria

---

### Inclusion (6)

- Clinical diagnosis of a GRIN-related neurodevelopmental disorder (GRIN-NDD)
- Presence of a pathogenic or likely pathogenic loss-of-function (LoF) variant in GRIN1, GRIN2A, GRIN2B, or GRIN2D
- Parent(s), caregiver(s), or legally authorised representative(s) have been informed of the nature of the study and have provided written informed consent.
- Participants who are able to do so have provided written informed consent or assent, according to local regulations and cognitive capacity.
- Parent(s)/caregiver(s) are willing and able to comply with study procedures and visits, in the opinion of the investigator.

... and 1 more (see full listing online)

### Exclusion (8)

- Age younger than 2 years at screening.
- Known hypersensitivity or intolerance to L-serine, placebo, or any excipients used in the study formulations.
- Presence of a clinically significant unstable medical condition (other than epilepsy) that, in the investigator's judgement, may place the participant at increased risk or interfere with study participation.
- Any other significant disease or disorder that may compromise participant safety, affect study outcomes, or impair the participant's ability to complete the study procedures.
- Inadequate supervision by parent(s) or caregiver(s), as judged by the investigator.

... and 3 more (see full listing online)

## Locations (3 total)

---

Hospices Civils de Lyon, Lyon, France  
Meyer Children's Hospital, Florence, Italy  
Children's Memorial Health Institute, Warsaw, Poland